I. A. Filippov
Research Subjects
I. A. Filippov has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
- L. A. Bakhova
Tyumen State Medical University
3 shared publications - M. S. Shvedskiy
Tyumen State Medical University
3 shared publications - A. N. Burdukova
City Polyclinic No. 17
1 shared publication - A. S. Loginova
Tyumen State Medical University
1 shared publication - D. A. Neverov
Oncology Center No. 1 of Yudin City Clinical Hospital
1 shared publication - E. A. Avsievich
Tyumen State Medical University
1 shared publication
Latest Publications
- Open Access
- 24 October 2026
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 15,p. 71-76
Real-world outcomes of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma: A retrospective cohort study
Introduction . Hepatocellular carcinoma (HCC) ranks sixth in morbidity and third in mortality among oncological diseases in the world. The combination of atezolizumab (a PD-L1 inhibitor) and bevacizumab (anti-VEGF) is the standard of first-line systemic therapy for unresectable HCC based on the results of the randomized IMbrave150 trial. Data on the use of this scheme in real clinical practice in the Russian population remains limited. Aim. To assess the efficacy and safety of atezolizumab plus bevacizumab in HCC patients in a real-world single-center setting. Materials and methods. This retrospective cohort study included 15 patients with histologically or clinically confirmed HCC receiving atezolizumab 1200 mg + bevacizumab 15 mg/kg IV every 3 weeks at Medical Center Medical City (Tyumen) from 2021 to 2025. Results . The median age of the patients included in the study was 49.6 years (range 27.6–73.1 years; mean 51.9 ± 12.3 years). Male patients prevailed – 10 (66.7%), 5 (33.3%) women. Stage BCLC C – 66.7% (10/15), BCLC B – 5/15 (33.3%). Viral hepatitis C was detected in 46.7% (7/15) of patients, hepatitis B in 13.3% (2/15), and the viral etiology of HCC was not established in 40.0% (6/15) of patients. The medians of PFS and OS were not reached, and the median follow-up was 16 months. The average number of courses conducted is 9 (range 2–21). The ORR was 37.7%. Adverse events were reported in 26.7% (4/15) of patients; the most significant were grade 1–2 autoimmune hepatitis, thrombocytopenia, and ischemic stroke. Conclusion . Real-world data confirm the efficacy and manageable toxicity of atezolizumab plus bevacizumab in HCC.
- 24 October 2026
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 15,p. 71-76
Open AccessReal-world outcomes of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma: A retrospective cohort study
Introduction . Hepatocellular carcinoma (HCC) ranks sixth in morbidity and third in mortality among oncological diseases in the world. The combination of atezolizumab (a PD-L1 inhibitor) and bevacizumab (anti-VEGF) is the standard of first-line systemic therapy for unresectable HCC based on the results of the randomized IMbrave150 trial. Data on the use of this scheme in real clinical practice in the Russian population remains limited. Aim. To assess the efficacy and safety of atezolizumab plus bevacizumab in HCC patients in a real-world single-center setting. Materials and methods. This retrospective cohort study included 15 patients with histologically or clinically confirmed HCC receiving atezolizumab 1200 mg + bevacizumab 15 mg/kg IV every 3 weeks at Medical Center Medical City (Tyumen) from 2021 to 2025. Results . The median age of the patients included in the study was 49.6 years (range 27.6–73.1 years; mean 51.9 ± 12.3 years). Male patients prevailed – 10 (66.7%), 5 (33.3%) women. Stage BCLC C – 66.7% (10/15), BCLC B – 5/15 (33.3%). Viral hepatitis C was detected in 46.7% (7/15) of patients, hepatitis B in 13.3% (2/15), and the viral etiology of HCC was not established in 40.0% (6/15) of patients. The medians of PFS and OS were not reached, and the median follow-up was 16 months. The average number of courses conducted is 9 (range 2–21). The ORR was 37.7%. Adverse events were reported in 26.7% (4/15) of patients; the most significant were grade 1–2 autoimmune hepatitis, thrombocytopenia, and ischemic stroke. Conclusion . Real-world data confirm the efficacy and manageable toxicity of atezolizumab plus bevacizumab in HCC.
- Open Access
- 1 January 2026
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 21,p. 142-146
Durable response to alectinib in a patient with advanced alk-positive non-small cell lung cancer: A case report
Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related morbidity and mortality worldwide. The discovery of anaplastic lymphoma kinase (ALK) gene translocations and the subsequent development of targeted therapies have transformed the prognosis for patients with advanced ALK-positive NSCLC accounting for about 3–7% of all NSCLC cases. With the introduction of targeted drugs, particularly tyrosine kinase inhibitors, treatment strategies for these patients have fundamentally changed. Alectinib, a second-generation tyrosine kinase inhibitor, has demonstrated high efficacy and improved progression-free survival as first-line therapy for ALK-positive NSCLC. This article presents a clinical case of a durable response to alectinib in a 43-year-old female patient with advanced ALK-positive lung adenocarcinoma with metastases to the lungs, pleura, and liver. First-line treatment with alectinib resulted in rapid and profound regression of tumor lesions, achieving a complete radiological response that has been maintained for 4 years. The therapy was characterized by a manageable safety profile. This observation demonstrates the potential for achieving long-term disease control and converting advanced ALK-positive NSCLC into a chronic, manageable condition with the use of alectinib as first-line therapy.
- 1 January 2026
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 21,p. 142-146
Open AccessDurable response to alectinib in a patient with advanced alk-positive non-small cell lung cancer: A case report
Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related morbidity and mortality worldwide. The discovery of anaplastic lymphoma kinase (ALK) gene translocations and the subsequent development of targeted therapies have transformed the prognosis for patients with advanced ALK-positive NSCLC accounting for about 3–7% of all NSCLC cases. With the introduction of targeted drugs, particularly tyrosine kinase inhibitors, treatment strategies for these patients have fundamentally changed. Alectinib, a second-generation tyrosine kinase inhibitor, has demonstrated high efficacy and improved progression-free survival as first-line therapy for ALK-positive NSCLC. This article presents a clinical case of a durable response to alectinib in a 43-year-old female patient with advanced ALK-positive lung adenocarcinoma with metastases to the lungs, pleura, and liver. First-line treatment with alectinib resulted in rapid and profound regression of tumor lesions, achieving a complete radiological response that has been maintained for 4 years. The therapy was characterized by a manageable safety profile. This observation demonstrates the potential for achieving long-term disease control and converting advanced ALK-positive NSCLC into a chronic, manageable condition with the use of alectinib as first-line therapy.
- Open Access
- 30 July 2025
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 10,p. 154-157
A clinical case of prolonged response to therapy for advanced hepatocellular carcinoma
Hepatocellular carcinoma (HCC) remains one of the leading causes of cancer mortality in the world, especially in regions with a high prevalence of viral hepatitis and cirrhosis of the liver. Systemic treatments remain the standard of treatment for common HCC. The most significant breakthrough was the appearance of a combination of the PD-L1 inhibitor Atezolizumab and the antiangiogenic drug Bevacizumab, which showed superiority over the tyrosine kinase inhibitor Sorafenib in key studies. A clinical case of treatment of a 61-year-old patient with advanced HCC on the background of cirrhosis of the liver of viral etiology, thrombosis of the portal vein and inferior vena cava with extrahepatic foci is presented. At the first stage, Atezolizumab and Bevacizumab were treated according to the first-line treatment protocol. Despite the development of immune-mediated toxic hepatitis and clinically significant bleeding, which required temporary discontinuation of treatment, repeated administration of the drugs led to a long-term stabilization of the process, confirmed by data from subsequent X-ray control studies. The case illustrates the effectiveness of a combination of immunotargeting therapy, including in patients with severe concomitant pathology, as well as the importance of a multidisciplinary approach and flexibility in correcting emerging complications.
- 30 July 2025
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 10,p. 154-157
Open AccessA clinical case of prolonged response to therapy for advanced hepatocellular carcinoma
Hepatocellular carcinoma (HCC) remains one of the leading causes of cancer mortality in the world, especially in regions with a high prevalence of viral hepatitis and cirrhosis of the liver. Systemic treatments remain the standard of treatment for common HCC. The most significant breakthrough was the appearance of a combination of the PD-L1 inhibitor Atezolizumab and the antiangiogenic drug Bevacizumab, which showed superiority over the tyrosine kinase inhibitor Sorafenib in key studies. A clinical case of treatment of a 61-year-old patient with advanced HCC on the background of cirrhosis of the liver of viral etiology, thrombosis of the portal vein and inferior vena cava with extrahepatic foci is presented. At the first stage, Atezolizumab and Bevacizumab were treated according to the first-line treatment protocol. Despite the development of immune-mediated toxic hepatitis and clinically significant bleeding, which required temporary discontinuation of treatment, repeated administration of the drugs led to a long-term stabilization of the process, confirmed by data from subsequent X-ray control studies. The case illustrates the effectiveness of a combination of immunotargeting therapy, including in patients with severe concomitant pathology, as well as the importance of a multidisciplinary approach and flexibility in correcting emerging complications.